SupplyManager℠  Log In Help

Product Comparison


  Sanofi Pasteur 49281071810 Seqirus USA Inc 70461041810 Seqirus USA Inc 33332041810 Seqirus USA Inc 70461031803 Seqirus USA Inc 33332031801
McKesson # 1085734 1087938 1087940 1087937 1087941
Description Flublok® Quadrivalent 2018 - 2019 Flu Vaccine 180 mcg / 0.5 mL Indicated For People 18 Years and Above Prefilled Syringe 0.5 mL Flucelvax® Quadrivalent 2018 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 4 Years of Age and Above Multiple Dose Vial 5 mL Afluria® Quadrivalent 2018 Flu Vaccine 60 mcg / 0.5 mL Indicated for People 6 Months of Age and Above Multiple Dose Vial 5 mL Flucelvax® Quadrivalent 2018 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 4 Years of Age and Above Prefilled Syringe 0.5 mL Afluria® Quadrivalent 2018 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 3 Years of Age and Above Prefilled Syringe 0.5 mL
Manufacturer # 4928107181070461041810333320418107046103180333332031801
Brand Flublok® Quadrivalent 2018 - 2019Flucelvax® Quadrivalent 2018Afluria® Quadrivalent 2018Flucelvax® Quadrivalent 2018Afluria® Quadrivalent 2018
Manufacturer Sanofi PasteurSeqirus USA IncSeqirus USA IncSeqirus USA IncSeqirus USA Inc
Invoice FLUBLOK 2018, QUAD SYR 0.5ML (10 DOSE/BX)FLUCELVAX 2018, QUAD MDV 5ML (10DOSE/VL)AFLURIA 2018, QUAD MDV 5ML (10DOSE/VL)FLUCELVAX 2018, QUAD SYR 0.5ML(10DOSE/BX)AFLURIA 2018, QUAD SYR 0.5ML (10DOSE/BX)
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Container Type Prefilled SyringeMultiple Dose VialMultiple Dose VialPrefilled SyringePrefilled Syringe
NDC Number 49281-0718-1070461041810333320418107046103180333332031801
Strength 180 mcg / 0.5 mL60 mcg / 0.5 mL60 mcg / 0.5 mL60 mcg / 0.5 mL60 mcg / 0.5 mL
User Indicated For People 18 Years and AboveIndicated For People 4 Years of Age and AboveIndicated For People 6 Months of Age and AboveIndicated For People 4 Years of Age and AboveIndicated For People 3 Years of Age and Above
Volume 0.5 mL5 mL5 mL0.5 mL0.5 mL
Application Flu VaccineFlu VaccineFlu VaccineFlu VaccineFlu Vaccine
Dosage Form InjectionInjectionInjectionInjectionInjection
Storage Requirements Requires RefrigerationRequires RefrigerationRequires RefrigerationRequires RefrigerationRequires Refrigeration
Type IntramuscularIntramuscularIntramuscularIntramuscularIntramuscular
UNSPSC Code 5120160851201608512016085120160851201608
Features and Benefits
  • Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza virus subtypes A and type B contained in the vaccine
  • Flublok Quadrivalent is approved for use in persons 18 years of age and older
  • Flublok contains no egg proteins, antibiotics, or preservatives
  • For the 2018 influenza season it is formulated to contain 180 mcg HA per 0.5 mL dose, with 45 mcg HA of each of the following 4 influenza virus strains: A/Michigan/45/2015 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008, and B/Phuket/3073/2013
  • FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
  • FLUCELVAX is approved for use in persons 4 years of age and older
  • FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2017-2018 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains: A/Singapore/GP1908/2015 IVR-180 (H1N1) (an A/Michigan/45/2015-like virus); A/Singapore/GP2050/2015 (H3N2) (an A/Hong Kong/4801/2014 – like virus); B/Utah/9/2014 (a B/Phuket/3073/2013-like virus); B/Hong Kong/259/2010 (a B/Brisbane/60/08-like virus)
  • FLUCELVAX QUADRIVALENT 5 mL multi-dose vial formulation contains no antibiotics
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 6 Months and older
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2017-2018 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2017-2018 Northern Hemisphere influenza season: A/Singapore/GP1908/2015 (H1N1), IVR-180A, A/Hong Kong/4801/2014 (H3N2), NYMC X-263B, B/Phuket/3073/2013 BVR-1B and B/Brisbane/46/2015
  • The multi-dose presentation contains thimerosal added as a preservative; each 0.5 mL dose contains 24.5 mcg of mercury
  • FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
  • FLUCELVAX is approved for use in persons 4 years of age and older
  • FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2017-2018 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains: A/Singapore/GP1908/2015 IVR-180 (H1N1) (an A/Michigan/45/2015-like virus); A/Singapore/GP2050/2015 (H3N2) (an A/Hong Kong/4801/2014 – like virus); B/Utah/9/2014 (a B/Phuket/3073/2013-like virus); B/Hong Kong/259/2010 (a B/Brisbane/60/08-like virus)
  • FLUCELVAX QUADRIVALENT 0.5 mL pre-filled syringes contain no preservative or antibiotics
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 3 Years of age and older
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2017-2018 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2017-2018 Northern Hemisphere influenza season: A/Singapore/GP1908/2015 (H1N1), IVR-180A, A/Hong Kong/4801/2014 (H3N2), NYMC X-263B, B/Phuket/3073/2013 BVR-1B and B/Brisbane/46/2015